Litigation Details for Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc. (Fed. Cir. 2022)

Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc. (Fed. Cir. 2022)

Docket		Date Filed	2022-08-25
Court	Court of Appeals for the Federal Circuit	Date Terminated	2024-04-11
Cause		Assigned To
Jury Demand		Referred To
Patents	10,335,397; 7,612,199; 7,902,206; 8,309,569; 8,642,573; 9,421,195; 9,623,001
Link to Docket	External link to docket

Details for Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc. (Fed. Cir. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-07-24	28		9,421,195, and 10,335,397 (“the HE Patents”); patents claiming a method of treating IBS-D, U.S. Patent Nos. 8,309,569…; 195 Patent"), and claims 11-12 of U.S. Patent No. 10,335,397 (the '"397 Patent"…9,421,195, 10,335,397 ("the HE Patents"), 8,309,569, and 10,765,667 ("the IBS-D Patents"…groups of patents: patents claiming a method of treating hepatic encephalopathy, U.S. Patent Nos. 8,642,573…(“the IBS-D Patents”); and patents claiming rifaximin in polymorphic form β, U.S. Patent Nos. 7,612,	External link to document
2024-04-11	71		claim 2 of U.S. Patent 8,309,569, claim 3 of U.S. Patent 10,765,667, claim 4 of U.S. Patent 7,612,199, and… U.S. Patent 8,624,573, claim 6 of U.S. Patent 9,421,195, and claims 11 and 12 of U.S. Patent 10,335,397…claim 2 of the ’569 patent, claim 3 of the ’667 patent, claim 4 of the ’199 patent, and claim 36 of the…streamlined to three groups of patents: • the ’573, ’195, and ’397 patents, directed to treating … HE (“the HE patents”); • the ’569 and ’667 patents, directed to treating IBS-D with	External link to document